{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:38Z","timestamp":1758845918435,"version":"3.44.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1053\/j.seminoncol.2012.11.010","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T20:18:00Z","timestamp":1360009080000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors"],"prefix":"10.1053","volume":"40","author":[{"given":"Matthew H.","family":"Kulke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2012.11.010_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MPA.0b013e3181917e4e","article-title":"Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas","volume":"38","author":"Strosberg","year":"2009","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ecl.2010.12.010","article-title":"New and emerging syndromes due to neuroendocrine tumors","volume":"40","author":"Vinik","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/MPA.0b013e3181b2bc7c","article-title":"Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors","volume":"38","author":"Song","year":"2009","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib4","first-page":"758","article-title":"Omeprazole in Zollinger-Ellison syndrome","volume":"310","author":"Lambers","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"Shojamanesh","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12022-007-0014-8","article-title":"Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas\u2014predominance of receptor subtype 4","volume":"18","author":"Portela-Gomes","year":"2007","journal-title":"Endocr Pathol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1445-5994.2007.01371.x","article-title":"Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma","volume":"37","author":"Healy","year":"2007","journal-title":"Intern Med J"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib8","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"de Herder","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.4082","article-title":"Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study","author":"Kvols","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib12","article-title":"Pasireotide LAR in patients with metastatic carcinoid tumors: pharmacokinetics (PK) and safety results from a randomized, multicenter, phase I study","author":"Wolin","year":"2009","journal-title":"2009 Gastrointestinal Cancers Symposium"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib13","article-title":"Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors","author":"Chan","year":"2010","journal-title":"American Society of Clinical Oncology Gastrointestinal Cancers Symposium"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","article-title":"Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Kwekkeboom","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib15","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib17","doi-asserted-by":"crossref","unstructured":"Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 29:2416\u201323.","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/02841869109092411","article-title":"The role of interferons in the management of carcinoid tumors","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/02841869309083918","article-title":"Treatment of carcinoid syndrome with recombinant interferon alpha-2a","volume":"32","author":"Di Bartolomeo","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib23","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/1097-0142(19910201)67:3<547::AID-CNCR2820670302>3.0.CO;2-J","article-title":"Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?","volume":"67","author":"Valimaki","year":"1991","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib27","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity ofr streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","article-title":"Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors","volume":"27","author":"McCollum","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib29","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib30","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1023\/A:1011632713360","article-title":"Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma","volume":"12","author":"Ramanathan","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdf064","article-title":"Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumors","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib32","first-page":"5846","article-title":"Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine","volume":"47","author":"Stevens","year":"1987","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib33","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000225389","article-title":"Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors","volume":"90","author":"Maire","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/07357900701206380","article-title":"Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide","volume":"25","author":"Schwarzberg","year":"2007","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib39","first-page":"4044","article-title":"A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol ASCO Annual Meeting Proc"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib40","article-title":"Phase I\/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET)","author":"Kulke","year":"2010","journal-title":"Gastrointestinal Cancers Symposium ASCO"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib41","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2002.06.110","article-title":"Clinical relevance of MGMT in the treatment of cancer","volume":"20","author":"Gerson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib42","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/bjc.1998.654","article-title":"O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma","volume":"78","author":"Middleton","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib43","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2006.07.4807","article-title":"Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide","volume":"25","author":"Chinot","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib44","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2006.06.3891","article-title":"Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study","volume":"24","author":"Brandes","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib46","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.1998.16.12.3851","article-title":"DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma","volume":"16","author":"Friedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib47","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib48","article-title":"A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors","author":"Kunz","year":"2010","journal-title":"ASCO Annual Meeting"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib49","article-title":"A Phase II trial of Folfox plus bevacizumab in advanced, progressive neuroendocrine tumors","author":"Bergsland","year":"2008","journal-title":"ASCO Gastrointestinal Cancer Symposium"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib50","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.22554","article-title":"Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors","volume":"109","author":"Zhang","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1535-6108(02)00031-4","article-title":"VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis","volume":"1","author":"Inoue","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib52","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2012.11.010_bib54","article-title":"Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET)","volume":"30","author":"Vinik","year":"2012","journal-title":"J Clin Oncol ASCO Annual Meeting"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib55","article-title":"MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study","volume":"25","author":"Hobday","year":"2007","journal-title":"J Clin Oncol ASCO Annual Meeting Proc"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib56","article-title":"A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC)","author":"Phan","year":"2010","journal-title":"J Clin Oncol ASCO Annual Meeting Proc"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.010_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10555-011-9290-3","article-title":"Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors","author":"Capdevilla","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and aging","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib60","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib61","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib64","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","author":"Kulke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.4002","article-title":"Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib66","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdf064","article-title":"Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib67","article-title":"Phase I\/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET)","author":"Kulke","year":"2010","journal-title":"2010 Gastrointestinal Cancers Symposium"},{"key":"10.1053\/j.seminoncol.2012.11.010_bib68","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:41Z","timestamp":1758804881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775412002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0093775412002096"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.010","relation":{},"ISSN":["0093-7754"],"issn-type":[{"type":"print","value":"0093-7754"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}